Skip to main content Skip to home page
 

Monoclonal Antibody Treatment

Deaconess is administering monoclonal antibody medications with emergency use authorization for treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Currently, we are administering the Regeneron product Casirivimab/Imdevimab.
  These medications are only for COVID-19 positive patients who:
  • are in their first 7 days of symptoms
  • are at high-risk for hospitalization, and meet any of the criteria below
Patients who meet any of this criteria must schedule an appointment with Deaconess Clinic LIVE to determine if they are good candidates for the medication.  Schedule your appointment here
 

Criteria for patients who may benefit from this treatment
The following medical conditions or other factors may place adults and pediatric patients (ages 12-17) at higher risk for severe COVID-19:
 

  • Older age (for example, age ≥65 years of age)

  • Obesity or being overweight; BMI ≥ 25   (BMI calculator)

  • Pregnancy

  • Chronic kidney disease

  • Diabetes

  • Immunosuppressive disease or currently receiving immunosuppressive treatment

  • Cardiovascular disease (including congenital heart disease) or hypertension

  • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)

  • Sickle cell disease

  • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)

  • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)

 All patients age 12+ must weigh at least 88 pounds to qualify for this treatment.  

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of REGEN-COV under the EUA is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progression to severe COVID, see CDC guidance.

If you believe you or a loved one may be a candidate for this treatment, schedule an appointment with Deaconess Clinic LIVE to determine if they are good candidates for the medication.  Schedule your appointment here.

Top Back to top